OBJECTIVES: Neuroendocrine tumor originates from several sites. This study was conducted to reveal the differences in clinical course of neuroendocrine tumors by the origin. METHODS: We reviewed data of patients diagnosed with neuroendocrine tumor between January 1996 and July 2007. RESULTS: A total of 371 patients were enrolled [pancreas 60, gastrointestinal (GI) tract 210, lung 35, other sites 46, unknown primary sites 20]. The primary tumor site correlated with the stage (P=0.000) and grade (P=0.000). At diagnosis, metastasis was observed in 28.3%, 6.7%, and 2.9% of the cases in pancreatic, GI, and pulmonary neuroendocrine tumors, respectively. Grade 3 neuroendocrine tumor was observed in 7.7%, 0.5%, and 0.0% in pancreatic, GI, and pulmonary neuroendocrine tumors. Overall survival was 116.0 months (95% confidence interval, 86.9-145.1). Overall survival was 116.0 months in pancreatic neuroendocrine tumor, not reached in GI neuroendocrine tumor and 120.0 months in pulmonary neuroendocrine tumor (P=0.024). The recurrence rate was 18.0%. It was 20.9%, 11.9%, and 2.9% in pancreatic, GI, and pulmonary neuroendocrine tumors (P=0.062). In multivariate analysis, stage, grade, and age were prognostic for overall survival (OS). Stage, grade, and sex were prognostic for disease-free survival. CONCLUSIONS: Neuroendocrine tumors from the pancreas, GI tract, and lung showed different clinical characteristics.
OBJECTIVES:Neuroendocrine tumor originates from several sites. This study was conducted to reveal the differences in clinical course of neuroendocrine tumors by the origin. METHODS: We reviewed data of patients diagnosed with neuroendocrine tumor between January 1996 and July 2007. RESULTS: A total of 371 patients were enrolled [pancreas 60, gastrointestinal (GI) tract 210, lung 35, other sites 46, unknown primary sites 20]. The primary tumor site correlated with the stage (P=0.000) and grade (P=0.000). At diagnosis, metastasis was observed in 28.3%, 6.7%, and 2.9% of the cases in pancreatic, GI, and pulmonary neuroendocrine tumors, respectively. Grade 3 neuroendocrine tumor was observed in 7.7%, 0.5%, and 0.0% in pancreatic, GI, and pulmonary neuroendocrine tumors. Overall survival was 116.0 months (95% confidence interval, 86.9-145.1). Overall survival was 116.0 months in pancreatic neuroendocrine tumor, not reached in GI neuroendocrine tumor and 120.0 months in pulmonary neuroendocrine tumor (P=0.024). The recurrence rate was 18.0%. It was 20.9%, 11.9%, and 2.9% in pancreatic, GI, and pulmonary neuroendocrine tumors (P=0.062). In multivariate analysis, stage, grade, and age were prognostic for overall survival (OS). Stage, grade, and sex were prognostic for disease-free survival. CONCLUSIONS:Neuroendocrine tumors from the pancreas, GI tract, and lung showed different clinical characteristics.
Authors: Aaron Vinik; Andrew Bottomley; Beata Korytowsky; Yung-Jue Bang; Jean-Luc Raoul; Juan W Valle; Peter Metrakos; Dieter Hörsch; Rajiv Mundayat; Arlene Reisman; Zhixiao Wang; Richard C Chao; Eric Raymond Journal: Target Oncol Date: 2016-12 Impact factor: 4.493
Authors: Katiuscha Merath; Fabio Bagante; Eliza W Beal; Alexandra G Lopez-Aguiar; George Poultsides; Eleftherios Makris; Flavio Rocha; Zaheer Kanji; Sharon Weber; Alexander Fisher; Ryan Fields; Bradley A Krasnick; Kamran Idrees; Paula M Smith; Cliff Cho; Megan Beems; Carl R Schmidt; Mary Dillhoff; Shishir K Maithel; Timothy M Pawlik Journal: J Surg Oncol Date: 2018-02-15 Impact factor: 3.454
Authors: Jordan J Baechle; Paula Marincola Smith; Marcus Tan; Carmen C Solórzano; Alexandra G Lopez-Aguiar; Mary Dillhoff; Eliza W Beal; George Poultsides; Eleftherios Makris; Flavio G Rocha; Angelena Crown; Clifford Cho; Megan Beems; Emily R Winslow; Victoria R Rendell; Bradley A Krasnick; Ryan Fields; Shishir K Maithel; Christina E Bailey; Kamran Idrees Journal: Ann Surg Oncol Date: 2020-04-23 Impact factor: 5.344
Authors: Stefan M Brunner; Florian Weber; Jens M Werner; Ayman Agha; Stefan A Farkas; Hans J Schlitt; Matthias Hornung Journal: BMC Surg Date: 2015-04-25 Impact factor: 2.102
Authors: Deyali Chatterjee; Nikolaos A Trikalinos; Greg A Williams; Jingxia Liu; William G Hawkins; Chet Hammill Journal: Pancreas Date: 2020-02 Impact factor: 3.243
Authors: Ashwin Soni; Epameinondas Dogeas; Krishna R Juluri; Christopher L Wolfgang; Ralph H Hruban; Matthew J Weiss Journal: Int J Surg Case Rep Date: 2014-06-20